tradmap

EXOZ Earnings EXOZYMES INC.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$1 -$1 $0 2023 2024 2025
EPS
Revenue (annual)
$0 $35035 $70069 2023 2024 2025
Revenue
Net income (annual)
-$9M -$5M $0 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$0 -$0 $0 Q3 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
EPS
Revenue (quarterly)
-$700 -$350 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$3M -$1M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–14 of 14
Q2 20262026-06-30-0.332026-08-1310-Q
Q1 20262026-03-31-0.282026-05-1410-Q
Q4 2025 (derived)2025-12-31-0.322026-03-3010-K
FY 20252025-12-31-1.092026-03-3010-K
Q3 20252025-09-30-0.272025-11-1310-Q
Q2 20252025-06-30-0.282025-08-1210-Q
Q1 20252025-03-31-0.222025-05-1210-Q
Q4 2024 (derived)2024-12-31-0.242025-03-3110-K
FY 20242024-12-31-0.892025-03-3110-K
Q3 20242024-09-30-0.272024-11-1210-Q
Q2 20242024-06-30-0.22——
Q1 20242024-03-31-0.16——
FY 20232023-12-31-0.33——
Q3 20232023-09-30-0.08——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.